December 9th, 2008
AstraZeneca PLC and Bristol-Myers Squibb Co. announced plan to extend in Japan. The pharmaceutical companies aims to sell type 2 diabetes drug called dapagliflozin in Japan.
The diabetes drug dapagliflozin, is a once daily drug. It is hoping to gain permission from health authorities in those countries to sell the drug in 2012.The companies said it was still too early to say when the drug might hit pharmacy shelves in Japan.
AstraZeneca’s shares rose 5 percent to 2,686 pence ($39.91) in London.
Filed under Diabetes, Diabetes Drug, NIDDM | Tags: 2012, AstraZeneca PLC, Bristol-Myers Squibb Co., dapagliflozin, type 2 diabetes | 1 Comment